Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745279 | 1.00 | EGFR (0.38) | EGFRERBB2SRCSLC22A12GAK | |
| SCHEMBL4745297 | 0.77 | SRC (0.51) | EGFRERBB2SRCGAK | |
| SCHEMBL4745298 | 0.77 | SRC (0.51) | EGFRERBB2SRCGAK | |
| SCHEMBL4745808 | 0.75 | EGFR (0.43) | EGFRERBB2SRCGAKLRRK2 | |
| SCHEMBL1724685 | 0.74 | NOS3 (0.39) | HTTALDH1A1NPC1 | |
| SCHEMBL1724687 | 0.74 | NOS3 (0.39) | HTTALDH1A1NPC1 | |
| SCHEMBL529236 | 0.72 | SRC (0.44) | EGFRERBB2SRCGAKHTT | |
| SCHEMBL13976998 | 0.72 | EGFR (0.46) | EGFRERBB2SRCGAKHTT | |
| SCHEMBL29775134 | 0.72 | EGFR (0.46) | EGFRERBB2SRCGAKHTT | |
| SCHEMBL15556832 | 0.70 | SLC22A12 (0.46) | SLC22A12GAKHTTALDH1A1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | EGFR 3929/4885ERBB2 1069/4885SRC 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.